Parkinson Disease (PD), the second most common neurodegenerative disease, affects more than one million people in North America, and no treatment has been proven to slow progression. Neuroimaging biomarkers have the potential to provide unbiased measurements of PD progression. Changes in dopamine receptors related to loss of nigrostriatal neurons may lead to """"""""dysregulation"""""""" of dopamine D2 and D3 receptors with a change in the D2:D3 ratio. A change in the D2:D3 ratio may play a key role in the behavioral consequences of CNS syndromes characterized by altered D2-like receptor function. However, the precise role of D3 in the pathophysiology and treatment remains to be determined. We previously developed a novel procedure to measure the density of D2 and D3 receptors in vitro and found that D3 receptors in striatum and substantia nigra change differently from D1 and D2 receptors in PD brains. We previously evaluated three different presynaptic PET tracers, [11C]DTBZ, [11C]CFT and [18F]fluoroDOPA for nigrostriatal neurons in monkeys given a wide range of doses of the selective dopaminergic neurotoxin MPTP. These PET studies demonstrated that striatal uptake of each of these linearly correlates with the number of nigrostriatal neurons (using unbiased stereologic counts of tyrosine hydroxylase [TH] immunostained neurons in nigra) but only when the loss of nigrostriatal neurons does not exceed 50%. In contrast, each of these tracers linearly correlates with in vitro measures of striatal dopamine. The in vivo PET measures correlated well with each other and with quantitative autoradiography of VMAT2 and DAT in striatum. Interestingly, motor ratings correlated fully with nigral cell counts and not with striatal dopamine or other terminal field measures, suggesting that factors other than just loss of striatal terminal fields influence motor parkinsonism. We hypothesize that changes in postsynaptic dopamine receptors may account for this discrepancy. In this project, we propose to conduct quantitative autoradiography measures of the postsynaptic dopamine receptors (D1, D2 and D3) in the striatum from brain tissues from 41 monkeys, 16 of them are treated with a wide range of single internal carotid MPTP doses (0 to 0.31 mg/kg);10 of them will be studied at different times after a MPTP (5 at 10 days and 5 at 3 weeks);3 groups of 5 will have a single dose of MPTP then treated for 2 months with chronic levodopa, a dopamine receptor agonist pramipexole or placebo. These additional measures are expected to provide a more complete reflection of the state of nigrostriatal neurons than presynaptic measures alone. The overall goal of this 2-year project is to determine how postsynaptic markers change after dopamine denervation to determine the most effective neuroimaging measures for accurate measurement of the severity of nigrostriatal injury. We also will investigate the effects chronic treatment with levodopa or pramipexole (a dopamine D3 receptor agonist) on these markers. The studies proposed in this grant have great potential for extending our understanding of the functional roles of dopamine receptor subtypes in PD progression.
Parkinson disease affects more than one million people in North America, and no treatment has been proven to slow progression. A reliable imaging biomarker is in urgent need for monitoring disease development and therapy output. Without a good biomarker, it's difficult for us to reach the ultimate goal of retarding the progression or reversing the inexorable decline of PD. The studies proposed in this grant have great potential on extending our understanding of the functional roles of dopamine receptor subtypes on dopamine transmission and regulation in the Parkinson disease. And this research has the potential for us to identify a reliable marker for the severity of the Parkinson disease.
|Zhou, Dong; Xu, Jinbin; Mpoy, Cedric et al. (2018) Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. Nucl Med Biol 66:26-31|
|Sahlholm, Kristoffer; Ielacqua, Giovanna D; Xu, Jinbin et al. (2017) The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. Psychopharmacology (Berl) 234:2019-2030|
|Laforest, Richard; Karimi, Morvarid; Moerlein, Stephen M et al. (2016) Absorbed radiation dosimetry of the D3-specific PET radioligand [18F]FluorTriopride estimated using rodent and nonhuman primate. Am J Nucl Med Mol Imaging 6:301-309|
|Peng, Xin; Wang, Qi; Mishra, Yogesh et al. (2015) Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Bioorg Med Chem Lett 25:519-23|
|Chu, Wenhua; Zhou, Dong; Gaba, Vrinda et al. (2015) Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for ?-Synuclein Fibrils. J Med Chem 58:6002-17|
|Sahlholm, Kristoffer; Liao, Fan; Holtzman, David M et al. (2015) Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. Biochem Biophys Res Commun 460:439-45|
|Zhao, Zhong-Qiu; Wan, Li; Liu, Xian-Yu et al. (2014) Cross-inhibition of NMBR and GRPR signaling maintains normal histaminergic itch transmission. J Neurosci 34:12402-14|
|Izzo, Nicholas J; Xu, Jinbin; Zeng, Chenbo et al. (2014) Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One 9:e111899|
|Gräff, Johannes; Joseph, Nadine F; Horn, Meryl E et al. (2014) Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 156:261-76|
|Bagchi, Devika P; Yu, Lihai; Perlmutter, Joel S et al. (2013) Binding of the radioligand SIL23 to ?-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One 8:e55031|
Showing the most recent 10 out of 24 publications